Lupin Limited is set to commercialize a newly approved antidepressant in Canada, marking a strategic expansion of its North American portfolio. The move strengthens the company’s specialty and central nervous system, or CNS, product pipeline in a market characterized by rising demand for mental health treatments. By leveraging its established regulatory and distribution infrastructure, Lupin aims to enhance revenue diversification and reinforce its global generics and branded formulations presence.